{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:58:56Z","timestamp":1790614736480,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In Germany, ~8 million patients take angiotensin receptor blockers (ARBs) and 2.25 million of them valsartan. In 2018, contamination of generic ARBs with probable carcinogenic nitrosamines resulted in more than 30 recalls. The impact of such a huge recall has never been explored in Europe. We analyzed the utilization of valsartan, all ARBs, and other alternative antihypertensive drugs in Germany. We used our database of anonymized dispensing data from &gt;80% of community pharmacies at the expense of the statutory health insurance (SHI) funds from January 2017 to December 2019. We analyzed 290.8 million prescriptions, including all oral mono- and fixed-dose combinations of ARBs and plausible alternatives, i.e. ACE inhibitors (ACEi), beta-blockers (BB), and calcium channel blockers (CCB). Utilization was calculated by defined daily doses per 1000 SHI-insured persons per day (DID). Valsartan use decreased substantially after the recalls in July 2018 from 39.0 to 14.2 DID (\u221264%) in the second quarter of 2019 and to 16.9 DID (\u221257%) in the fourth quarter of 2019. Simultaneously, the use of alternative ARBs increased from 77.7 DID in the second quarter of 2018 to 121.9 DID (+57%) in the fourth quarter of 2019, mainly due to an increase of candesartan dispensing to 99.8 DID (+73%). There were no changes in the utilization of ACEi, BB, or CCB. The majority of recalled generic valsartan products were replaced by other ARBs, predominantly candesartan, despite documented drug shortages. In contrast to previous safety warnings\/recalls, our data do not suggest an under-prescription of antihypertensives during this period.<\/jats:p>","DOI":"10.1038\/s41371-020-00425-z","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T14:03:15Z","timestamp":1602684195000},"page":"903-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8055-8519","authenticated-orcid":false,"given":"Ulrike Maria","family":"Rudolph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-295X","authenticated-orcid":false,"given":"Salka","family":"Enners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Kieble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-7322","authenticated-orcid":false,"given":"Martin","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"425_CR1","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u20133104.","journal-title":"Eur Heart J"},{"key":"425_CR2","unstructured":"Bundesministerium f\u00fcr Gesundheit. Verunreinigungen von Arzneimitteln mit Valsartan. Berlin: Bundesministerium f\u00fcr Gesundheit; 2018. https:\/\/kleineanfragen.de\/bundestag\/19\/4073."},{"key":"425_CR3","unstructured":"BfArM. Valsartan: chargenbezogener R\u00fcckruf valsartanhaltiger Arzneimittel, deren Wirkstoff von dem chinesischen Hersteller Zhejiang Huahai Pharmaceutical produziert wurde: Pressemitteilung 5\/2018. Bonn, DE: BfArM; 2018. https:\/\/www.bfarm.de\/SharedDocs\/Pressemitteilungen\/DE\/2018\/pm5-2018.html."},{"key":"425_CR4","doi-asserted-by":"publisher","first-page":"k3855","DOI":"10.1136\/bmj.k3855","volume":"362","author":"R Banzi","year":"2018","unstructured":"Banzi R, Bertele\u2019 V. Regulatory response to contaminated valsartan. BMJ. 2018;362:k3855.","journal-title":"BMJ"},{"key":"425_CR5","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMp1901657","volume":"380","author":"JB Byrd","year":"2019","unstructured":"Byrd JB, Chertow GM, Bhalla V. Hypertension hot potato\u2014anatomy of the angiotensin-receptor blocker recalls. N Engl J Med. 2019;380:1589\u20131591.","journal-title":"N Engl J Med"},{"key":"425_CR6","unstructured":"ABDA. Online-Nachricht: AMK: Liste der (Chargen-)R\u00fcckrufe Sartan-haltiger Arzneimittel. Berlin, DE: ABDA; 2019. https:\/\/www.abda.de\/fuer-apotheker\/arzneimittelkommission\/amk-nachrichten\/detail\/online-nachricht-amk-liste-der-chargen-rueckrufe-sartan-haltiger-arzneimittel\/."},{"key":"425_CR7","doi-asserted-by":"publisher","first-page":"e0215837","DOI":"10.1371\/journal.pone.0215837","volume":"14","author":"JM Phuong","year":"2019","unstructured":"Phuong JM, Penm J, Chaar B, Oldfield LD, Moles R. The impacts of medication shortages on patient outcomes: a scoping review. PloS One. 2019;14:e0215837.","journal-title":"PloS One"},{"key":"425_CR8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.healthpol.2018.09.005","volume":"122","author":"A Said","year":"2018","unstructured":"Said A, Goebel R, Ganso M, Zagermann-Muncke P, Schulz M. Drug shortages may compromise patient safety: results of a survey of the reference pharmacies of the Drug Commission of German pharmacists. Health policy. 2018;122:1302\u20131309.","journal-title":"Health policy"},{"key":"425_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamainternmed.2018.8251","volume":"179","author":"A Hantel","year":"2019","unstructured":"Hantel A, Siegler M, Hlubocky F, Colgan K, Daugherty CK. Prevalence and severity of rationing during drug shortages: a national survey of health system pharmacists. JAMA Intern Med. 2019;179:710\u2013711.","journal-title":"JAMA Intern Med"},{"key":"425_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.mayocp.2013.11.014","volume":"89","author":"ER Fox","year":"2014","unstructured":"Fox ER, Sweet BV, Jensen V. Drug shortages: a complex health care crisis. Mayo Clin Proc. 2014;89:361\u2013373.","journal-title":"Mayo Clin Proc"},{"key":"425_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/jdv.15952","volume":"34","author":"GA Hofmann","year":"2020","unstructured":"Hofmann GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B. The frequency of photosensitizing drug dispensings in Austria and Germany: a correlation with their photosensitizing potential based on published literature. J Eur Acad Dermatol Venereol. 2020;34:589\u2013600.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"425_CR12","unstructured":"GKV-Spitzenverband. Berichte zum Quartalsende. https:\/\/www.gkv-gamsi.de\/gamsi_berichte\/quartalsberichte.jsp. Berlin: 2019."},{"key":"425_CR13","unstructured":"ABDATA Pharma data service. ABDA database and ABDA articles. Bi\u2010Monthly Update. Eschborn: Avoxa\u2014Mediengruppe Deutscher Apotheker GmbH; 2019."},{"key":"425_CR14","unstructured":"German Institute of Medical Documentation and Information (DIMDI). German anatomical therapeutic chemical (ATC)-classification with defined daily doses (DDD) for Germany. Bonn, DE: German Institute of Medical Documentation and Information (DIMDI); 2019. https:\/\/www.dimdi.de\/dynamic\/en\/drugs\/atc-classification\/."},{"key":"425_CR15","unstructured":"Norwegian Institute of Public Health. Use of ATC\/DDD Oslo, Norway. Norwegian Institute of Public Health; 2018. https:\/\/www.whocc.no\/use_of_atc_ddd\/."},{"key":"425_CR16","doi-asserted-by":"crossref","unstructured":"Elseviers M, Wettermark B, Almarsd\u00f3ttir AB, Andersen M, Benko R, Bennie M, et al. Drug utilization research\u2014methods and applications. Chapter 6. In: Measurement units of drug utilization. Hoboken, NJ: John Wiley & Sons Inc. Chichester, West Sussex; 2016.","DOI":"10.1002\/9781118949740"},{"key":"425_CR17","unstructured":"Federal Ministry of Health. KM6\u2010statistics. Berlin, DE: Federal Ministry of Health; 2019. https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/zahlen-und-fakten-zur-krankenversicherung\/mitglieder-und-versicherte.html."},{"key":"425_CR18","first-page":"786","volume":"14","author":"G Gradl","year":"2016","unstructured":"Gradl G, Krieg E-M, Schulz M. Evaluation of pharmaceutical concerns in Germany: frequency and potential reasons. Pharm Pract. 2016;14:786.","journal-title":"Pharm Pract"},{"key":"425_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.119.044494","volume":"141","author":"CA Jackevicius","year":"2020","unstructured":"Jackevicius CA, Krumholz HM, Chong A, Koh M, Ozaki AF, Austin PC, et al. Population impact of generic valsartan recall. Circulation. 2020;141:411\u2013413.","journal-title":"Circulation"},{"key":"425_CR20","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667\u201375.","journal-title":"N Engl J Med"},{"key":"425_CR21","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2165\/11319460-000000000-00000","volume":"69","author":"HR Black","year":"2009","unstructured":"Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs. 2009;69:2393\u20132414.","journal-title":"Drugs"},{"key":"425_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.13955","volume":"74","author":"PM Gunasekaran","year":"2019","unstructured":"Gunasekaran PM, Chertow GM, Bhalla V, Byrd JB. Current status of angiotensin receptor blocker recalls. Hypertension. 2019;74:1275\u20131278.","journal-title":"Hypertension"},{"key":"425_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jama.2019.17521","volume":"323","author":"RJ Desai","year":"2020","unstructured":"Desai RJ, Sarpatwari A, Gautam N, Lii J, Fischer MA, Gagne JJ. Changes in utilization of generic angiotensin receptor blockers following product recalls in the United States. JAMA. 2020;323:87\u201389.","journal-title":"JAMA"},{"key":"425_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1742-1241.2011.02633.x","volume":"65","author":"AM Grosso","year":"2011","unstructured":"Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract. 2011;65:253\u2013263.","journal-title":"Int J Clin Pract"},{"key":"425_CR25","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","volume":"394","author":"MA Suchard","year":"2019","unstructured":"Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816\u20131826.","journal-title":"Lancet"},{"key":"425_CR26","unstructured":"Gradl G. In den Jahren 2017 bis 2019 hat sich der Anteil nicht verf\u00fcgbarer Rabattarzneimittel nahezu vervierfacht: DAPI number of month March 2020. Berlin: DAPI; 2020. www.dapi.de\/en\/news\/number-of-the-month\/details\/article\/in-den-Jahren-2017-bis-2019-hat-sich-der-anteil-nicht-verfuegbarer-rabattarzneimittel-nahezu-vervier\/."},{"key":"425_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11906-020-1021-0","volume":"22","author":"AM Berrido","year":"2020","unstructured":"Berrido AM, Byrd JB. Angiotensin receptor blockers and the risk of cancer: insights from clinical trials and recent drug recalls. Curr Hypertens Rep. 2020;22:20.","journal-title":"Curr Hypertens Rep"},{"key":"425_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2146\/ajhp150277","volume":"73","author":"K Hall","year":"2016","unstructured":"Hall K, Stewart T, Chang J, Freeman MK. Characteristics of FDA drug recalls: a 30-month analysis. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharmacists. 2016;73:235\u2013240.","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharmacists"},{"key":"425_CR29","first-page":"2065","volume":"162","author":"R Goebel","year":"2017","unstructured":"Goebel R, Ganso M, Zagermann-Muncke P, Said, A, Schulz M. Arzneimittelengp\u00e4sse\u2014Gefahr f\u00fcr die Patientensicherheit. Pharm Ztg. 2017;162:2065\u20132067.","journal-title":"Pharm Ztg"},{"key":"425_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.18553\/jmcp.2013.19.9.783","volume":"19","author":"M McLaughlin","year":"2013","unstructured":"McLaughlin M, Kotis D, Thomson K, Harrison M, Fennessy G, Postelnick M, et al. Effects on patient care caused by drug shortages: a survey. J Manag Care Pharm. 2013;19:783\u2013788.","journal-title":"J Manag Care Pharm"},{"key":"425_CR31","unstructured":"European medicines agency. Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group: European Commission final decision: European medicines agency. Amsterdam, NL: European medicines agency; 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group."},{"key":"425_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jval.2020.04.167","volume":"23","author":"M Schulz","year":"2020","unstructured":"Schulz M, Kieble M, Enners S, Laufs U, B\u00f6hm M, Kintscher U, Mahfoud F. Impact on antihypertensive prescribing after the Dear Healthcare Professional letter on increased risk of skin cancer related to hydrochlorothiazide [abstract]. Value Health. 2020;23:102.","journal-title":"Value Health"},{"key":"425_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","volume":"78","author":"SA Pedersen","year":"2018","unstructured":"Pedersen SA, Gaist D, Schmidt SAJ, H\u00f6lmich LR, Friis S, Pottegard A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78:673\u2013681.","journal-title":"J Am Acad Dermatol"},{"key":"425_CR34","unstructured":"BfArM. Rote-Hand-Brief zu Hydrochlorothiazid (HCT): Risiko von nichtmelanozyt\u00e4rem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)]. Bonn, DE: BfArM; 2020. www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharakovigilanz\/DE\/RHB\/2018\/rhb-hydrochorothiazid.html."},{"key":"425_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41371-019-0190-2","volume":"33","author":"L Faconti","year":"2019","unstructured":"Faconti L, Ferro A, Webb AJ, Cruickshank JK, Chowienczyk PJ. Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. J Hum Hypertens. 2019;33:257\u2013258.","journal-title":"J Hum Hypertens"},{"key":"425_CR36","doi-asserted-by":"publisher","first-page":"e005536","DOI":"10.1161\/CIRCOUTCOMES.119.005536","volume":"12","author":"SG Al-Kindi","year":"2019","unstructured":"Al-Kindi SG, Oliveira GH. Abrupt increase in reporting of neoplasms associated with valsartan after medication recall. Circ Cardiovasc Qual Outcomes. 2019;12:e005536.","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00425-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:20:59Z","timestamp":1634170859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00425-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1038\/s41371-020-00425-z","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"UR has received scientific support and speaker honoraria from Bayer, Berlin Chemie, and Bristol Myers Squibb, all outside the submitted work. FM is supported by Deutsche Gesellschaft f\u00fcr Kardiologie (DGK) and has received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic, and ReCor Medical, all outside the submitted work. FM and MB are supported by the Deutsche Forschungsgemeinschaft (SFB TRR219). UL has received speaker honoraria from Bayer, Boehringer Ingelheim, Novartis and Servier, all outside the submitted work. MS has received speaker honoraria from Novartis and Sanofi, all outside the submitted work. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}